Kode Technology Illustrated Technical Manual
Kode Biotech is pleased to announce that the Kode Technology Illustrated Technical Manual eBook is n…
Kode Biotech Limited (KBL) is a private New Zealand company established in 1996 to develop, commercialise and license Kode™ Technology.
Vision: Change the surface of biotechnology
Mission: Ignite a revolution with Kode™ surface modification nanotechnology by enabling our partners to enhance existing and create next-generation products with a technology to shape life.
KBL is the holder and parent of a number of subsidiary companies that license Kode™ Technology for various sectors and uses. These subsidiaries include Kode Biotech Materials, Kode Diagnostics, Kode Implant Coatings, Kode Wound Care, Kode Veterinary and GlycoNZ, a distributor of glycoconjugate products.
Kode™ Technology has already been licensed to several large companies, and an example of a product incorporating Kode™ Technology that is already in the market is Securacell™ and cancer therapy in human clinical trials with BiolineRx.
KBL and its subsidiaries are independent companies, situated in Auckland, New Zealand.
The academic resource for Kode™ Technology includes journal articles, videos, MSDS, technical bulletins and FAQs.
Purchase high-quality carbohydrate products, glycolipid Kode FSL constructs and glycoconjugates probes for glycobiology.
Founder & CEO
CSO
CIPO
Founder & CEO
Chairman
Director
Kode Biotech is pleased to announce that the Kode Technology Illustrated Technical Manual eBook is n…
By Jamie Morton Original Article Kiwi-developed technology – using “synthetic paint” to coat the out…
Third place Berlin Falling Walls Lab Finale 2018 Original Article Auckland University of Technology&…
Original Article Professor Stephen Henry has been awarded the Pickering Medal by the Royal Society T…
Simon Pound | Business is Boring boss | The Spinoff article Business is Boring is a weekly podcast s…
Hamilton, NZ, 18 May 2017 – Twelve finalists have been selected for the fifth annual KiwiNet Researc…
Area of focus: Our focus is to get Kode Technology licensed broadly as a core component that enables…
Original article by Lucy Warhurst, Newshub A New Zealand-made technology behind a promising bre…
BioLineRx Buys U.K. Cancer Immunotherapeutics Firm Agalimmune GEN News Highlights Original Article B…
Technology that transforms your cells | Stephen Henry | TEDxChristchurch What if you could make your…
Surgical implants can be life-changing. Millions of people across the globe have had their mobility …
By HENRY OLIVER, idealog NZ Innovator Awards Kode Biotech wins the Supreme NZ Innovator Award 2015 f…
Newshub Stephen Henry took home the prize of Supreme Innovator award at the NZ Innovators Awards. Hi…
By Chris Keall Under the terms of the agreement, Kode may receive up to £21 million in development a…
Kode Biotech Limited concluded two therapeutic agreements. The first, with a publicly listed French …
Contact us 24/7.
We are here for your support.
Product catalogue and pricing on glyconz.com
19 Mount Street, Scott Laboratory Building, Auckland 1010, New Zealand